Browsing in Public Health

Building a National Capability to Monitor and Assess Medical Countermeasure Use During a Public Health Emergency: Going Beyond the Last Mile

Click for larger image
List Price:$45.00
Your Price:$40.50
Savings:$4.50 (10%)
Availability:Usually ships within 2-4 weeks Available online Available online

Product Description
During public health emergencies (PHEs) involving chemical, biological, radiological, or nuclear threats or emerging infectious diseases, medical countermeasures (MCMs) (e.g., drugs, vaccines, devices) may need to be dispensed or administered to affected populations to help mitigate the human health impact of the threat. The optimal MCMs determined for use during an emergency might be U.S. Food and Drug Administration (FDA) approved but used in unapproved ways (e.g., in a new age group or against a new agent) FDA approved using animal models because human efficacy testing is not ethical or feasible; or not yet FDA approved for any indication.

Product Information
Binding: Softcover
Specs: 105 pages | .47 Lbs
Edition: 1
Publisher: National Academies Press | Publish Date 12/17 | Copyright 2017

Add To Cart

Questions? Contact us here